Global Overweight and oBesE GLOBE Patient Registry to Develop and Use New Tools Measuring Severity, Quality of Life, and Costs for People with BMI Over 25

What this Trial Is About

Researchers are conducting this observational study to create specialized tools that measure the severity, quality of life, and costs related to overweight and obesity for individuals with a body mass index BMI over 25. The study highlights the lack of comprehensive instruments for people who are overweight or extremely obese, especially those not receiving certain treatments like GLP-1 therapy. It aims to combine patient and clinician perspectives to improve severity measures and support early intervention strategies. The study involves systematically assessing symptoms, comorbidities, health-related quality of life HRQoL, and economic impacts across a wide range of participants with BMI above 25. It excludes those on GLP-1 therapy. There are no drug or device interventions instead, participants complete surveys and questionnaires that help develop disease-specific and quality of life instruments over about two months. Participants will be involved in completing surveys and study activities in English, reporting their BMI and health status. The main outcome is the development of a disease-specific questionnaire within two months, along with a quality of life tool. Researchers will collect data on symptoms, costs, and patient experiences to better understand the burden of overweight and obesity. Participation is voluntary, and the study includes adults aged 18 and older.

Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.